https://scholars.lib.ntu.edu.tw/handle/123456789/484115
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | YU-YUN SHAO | en_US |
dc.contributor.author | Hu F.-C. | en_US |
dc.contributor.author | JIN-TUNG LIANG | en_US |
dc.contributor.author | Chiu W.-T. | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.creator | Yang C.-H.;Cheng A.-L.;Chiu W.-T.;Liang J.-T.;Hu F.-C.;YU-YUN SHAO | - |
dc.date.accessioned | 2020-04-10T12:16:14Z | - |
dc.date.available | 2020-04-10T12:16:14Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0929-6646 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955901055&doi=10.1016%2fS0929-6646%2810%2960064-2&partnerID=40&md5=6d83eb59b1f48b5374267c517427186e | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/484115 | - |
dc.description.abstract | Background/Purpose: Hypersensitivity reactions during oxaliplatin infusion are a major problem associated with its use. In this study, we investigated the characteristics and risk factors of these events. Methods: All patients who had received oxaliplatin in outpatient settings from January 2006 to March 2007 in a medical center were enrolled in this retrospective study. All the oxaliplatin infusions were reviewed. Manifestations of hypersensitivity reactions and clinicopathological variables were collected from medical records. Results: Three hundred and eighty-three patients with 3648 oxaliplatin infusions were reviewed. Fortyseven patients (12.7%) developed hypersensitivity reactions, which occurred after a median of 10 infusions. The median time of onset from start of infusion was 40 minutes. Most presentations (90.7%) were mild to moderate, but rechallenge with oxaliplatin led to a high chance of further reactions (71.4%). Cutaneous symptoms were the most prevalent manifestation, followed by respiratory symptoms. With each repeated infusion, the incidence of hypersensitivity reactions increased. Higher oxaliplatin dose per infusion was an independent risk factor for such reactions. Conclusion: Patients treated with oxaliplatin for an extended period have a greater risk of oxaliplatinrelated hypersensitivity reactions. ?2010 Elsevier & Formosan Medical Association. | - |
dc.publisher | Elsevier B.V. | - |
dc.relation.ispartof | Journal of the Formosan Medical Association | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | dexamethasone; diphenhydramine; granisetron; oxaliplatin; ranitidine; antineoplastic agent; oxaliplatin; platinum complex; adult; aged; anaphylactic shock; article; biliary tract cancer; cancer adjuvant therapy; cancer chemotherapy; cancer palliative therapy; chill; colorectal cancer; consciousness disorder; corticosteroid therapy; digestive system disease; dose response; drug fatality; drug fever; drug hypersensitivity; esophagus carcinoma; female; human; hypertension; jejunum cancer; liver cell carcinoma; major clinical study; male; medical record review; nasopharynx carcinoma; outpatient; pancreas cancer; peripheral neuropathy; premedication; provocation test; respiratory tract disease; retrospective study; risk assessment; risk factor; skin manifestation; stomach cancer; drug administration; drug hypersensitivity; intravenous drug administration; middle aged; proportional hazards model; time; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Young Adult | - |
dc.title | Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/S0929-6646(10)60064-2 | - |
dc.identifier.pmid | 20497869 | - |
dc.identifier.scopus | 2-s2.0-77955901055 | - |
dc.relation.pages | 362-368 | - |
dc.relation.journalvolume | 109 | - |
dc.relation.journalissue | 5 | - |
item.fulltext | no fulltext | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.orcid | 0000-0001-7334-1912 | - |
crisitem.author.orcid | 0000-0002-0264-7735 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。